CLINICAL_TRIALS ClinicalTrials.gov record update

St. Jude ELIOT: Phase 1 Evaluation of LY2606368, a Molecularly-Targeted CHK1/2 Inhibitor Therapy, in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04023669
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:52.720141+00:00
Published At: 2025-02-07T00:00:00+00:00
Record Updated At: 2025-02-07
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Brain Tumor", "Brain Tumor, Recurrent", "Brain Tumor, Refractory", "Brain Tumor, Pediatric", "Medulloblastoma", "Medulloblastoma Recurrent", "Medulloblastoma, Non-WNT/Non-SHH", "Medulloblastoma, Non-WNT/Non-SHH, Group 3", "Medulloblastoma, Non-WNT/Non-SHH, Group 4", "Brain Cancer", "CNS Cancer", "CNS Tumor", "CNS Neoplasm"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-02-07"
protocolSection.identificationModule.nctId: "NCT04023669"
protocolSection.identificationModule.officialTitle: "St. Jude ELIOT: Phase 1 Evaluation of LY2606368, a Molecularly-Targeted CHK1/2 Inhibitor Therapy, in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.